sorafenib has been researched along with azacitidine in 20 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (azacitidine) | Trials (azacitidine) | Recent Studies (post-2010) (azacitidine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 7,474 | 479 | 3,782 |
| Protein | Taxonomy | sorafenib (IC50) | azacitidine (IC50) |
|---|---|---|---|
| DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | 0.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Connock, M; Hyde, C; Moore, D | 1 |
| Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA | 1 |
| Choi, WW; Chow, HC; Gill, H; Ip, AH; Kwong, YL; Leung, AY; Man, CH | 1 |
| Ford, LA; Freyer, CW; Griffiths, EA; Muppidi, MR; Portwood, S; Thompson, JE; Wang, ES; Wetzler, M | 1 |
| Chandra, S; Dahl, NA; McMasters, RL; Michaels, ST; O'Brien, MM | 1 |
| Alvares, C; Chakraborty, M; Conner, C; Gosrani, D; Mahdi, AJ; Rayment, R; Rees, A; Wilson, K | 1 |
| Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T | 1 |
| Gu, J; Huang, W; Mao, X; Wang, Y; Wang, Z; Xiao, M; Zhu, L | 1 |
| Blaise, D; Charbonnier, A; D'Incan, E; Mohty, B; Rey, J; Sid, S; Vey, N | 1 |
| Comerford, CM; Langabeer, SE; Murphy, PT; Quinn, J | 1 |
| Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Estrov, Z; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Levis, M; Ohanian, M; Patel, K; Pierce, S; Ravandi, F; Richie, MA | 1 |
| Busschaert, P; Cappuyns, S; Dekervel, J; Galle, E; Lambrechts, D; Roskams, T; Thienpont, B; Van Cutsem, E; Van Haele, M; van Pelt, J; Venken, T; Verslype, C | 1 |
| Kuo, DJ; Severson, E; Wong, V; Woolbright, WC | 1 |
| Cho, MK; Heo, JY; Kim, S; Kim, WI; Park, TH; Yoon, SY | 1 |
| Giubellino, A; Nasrollahi, E; Rashidi, A | 1 |
| Dhangar, S; Ghatanatti, J; Mathan S, LP; Sawant, L; Shah, A; Shanmukhaiah, C; Vundinti, BR | 1 |
2 review(s) available for sorafenib and azacitidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
4 trial(s) available for sorafenib and azacitidine
| Article | Year |
|---|---|
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Survival Rate; Tandem Repeat Sequences; Young Adult | 2013 |
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Salvage Therapy; Sorafenib; Survival Rate | 2017 |
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Remission Induction; Salvage Therapy; Sorafenib; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2018 |
14 other study(ies) available for sorafenib and azacitidine
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer.
Topics: Antineoplastic Agents; Azacitidine; Benzenesulfonates; Biomedical Research; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Models, Economic; Models, Statistical; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Technology Assessment, Biomedical; United Kingdom | 2011 |
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Monocytes; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2015 |
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Sorafenib; Stem Cell Transplantation | 2016 |
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pregnancy; Pregnancy Complications, Neoplastic; Sorafenib; Treatment Outcome | 2018 |
Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Postoperative Care; Recurrence; Retreatment; Sorafenib; Treatment Outcome | 2017 |
Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; DNA Mutational Analysis; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Circulating Tumor DNA; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Sorafenib | 2020 |
The Application of Next-generation Sequencing Tumor Molecular Profiling in the Diagnosis and Management of a Case of Acute Myelogenous Leukemia With MLL-PTD in a Pediatric Heart Transplant Recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Combined Modality Therapy; Disease Management; Female; Gene Duplication; Heart Transplantation; Hematopoietic Stem Cell Transplantation; High-Throughput Nucleotide Sequencing; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myeloid-Lymphoid Leukemia Protein; Prognosis; Sorafenib; Tandem Repeat Sequences | 2021 |
Case of neutrophilic eccrine hidradenitis resembling acanthosis nigricans in a patient with acute myeloid leukemia associated with azacitidine and sorafenib.
Topics: Acanthosis Nigricans; Azacitidine; Hidradenitis; Humans; Leukemia, Myeloid, Acute; Sorafenib | 2021 |
Erythema nodosum after azacitidine in a patient with acute myeloid leukemia.
Topics: Adult; Azacitidine; Erythema Nodosum; Humans; Leukemia, Myeloid, Acute; Male; Recurrence; Sorafenib | 2023 |
Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement.
Topics: Azacitidine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic | 2023 |